Ahead of ARWR’s phase III SHASTA-3/4 in 3Q26, we have published a new in-depth report on the ARWR/IONS sHTG debate, challenging the view that Ionis is comfortably ahead. The key question is straightforward: can SHASTA-3/4 deliver a statistically significant reduction in acute pancreatitis? And if so, will that reduction look better than what has already been shown with olezarsen?

We answer this and other debate questions that matter most going into the catalyst